Latest news with #Prolia
Yahoo
29-05-2025
- Business
- Yahoo
Denosumab Market Report 2025-2029 & 2034: Strategic Collaborations and Digital Health Pave the Way for Innovations, First-Line Treatment Boyoubei Gains Traction
Explore the booming denosumab market, projected to reach $5.59 billion by 2029 with a CAGR of 10.9%. Key growth drivers include osteoporosis prevalence, innovative treatments, and strategic partnerships. Major players like Amgen and Boan Biotech are at the forefront, with North America leading and Asia-Pacific emerging rapidly. Denosumab Market Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Denosumab Market Report 2025" has been added to offering. The denosumab market has experienced robust growth, increasing from $3.27 billion in 2024 to an expected $3.7 billion in 2025, registering a CAGR of 13.1%. This growth has been supported by clinical trials, research advancements, FDA approvals, an increased focus on bone health, and strategic partnerships. As the demand continues, projections indicate the market will reach $5.59 billion by 2029, with a CAGR of 10.9% for the forecast period. This anticipated growth is linked to a rising incidence of bone metastases and advancements in both cancer therapies and osteoporosis awareness. Recent studies, including one from the National Center for Biotechnology Information, highlight the prevalence of osteoporosis, with figures such as a 12.7% prevalence in women diagnosed by physicians in Canada. These statistics underscore the expanding need for effective treatments like denosumab, which targets bone resorption, thereby aiding in reducing fracture risks. Key market players are enhancing their offerings, as seen with Boan Biotech's November 2022 introduction of Boyoubei, a denosumab biosimilar. Securing approval from China's National Medical Products Administration, this biosimilar stands unique as the first to receive global marketing approval. Strategies include penetration into the U.S. and European markets with hopes to impact osteoporosis treatment guidelines. Strategic collaborations are shaping the market. For instance, in June 2022, Organon entered into a partnership with Henlius to commercialize biosimilar candidates referencing Prolia and Xgeva (Denosumab). This alliance emphasizes Organon's commitment to affordable healthcare, particularly focusing on women's health. Major companies in this market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, and Amgen Inc., among others. With North America leading the market in 2024, Asia-Pacific is expected to be the fastest-growing region due to rising healthcare advancements and awareness. The denosumab market includes sales of calcium and vitamin D supplements, with values representing factory-gate sales, encompassing the goods sold by manufacturers to various entities. The market also covers comprehensive reports addressing market size, regional shares, and detailed segments, providing a holistic perspective of industry trends. This market, valued in USD unless specified, includes revenues from direct sales, highlighting its importance across multiple geographies, including Asia-Pacific, Western and Eastern Europe, North America, and beyond. Denosumab, as a monoclonal antibody, plays a critical role in treating bone-related conditions, specifically osteoporosis and bone metastases, revealing its ongoing importance in the healthcare landscape. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $3.7 Billion Forecasted Market Value (USD) by 2029 $5.59 Billion Compound Annual Growth Rate 10.9% Regions Covered Global Scope: Markets Covered: By Drug Classification:Prolia, Xgeva, Others By Type:60 mg, 120 mg By End-Users:Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers Companies Featured Johnson & Johnson F. Hoffmann-La Roche Ltd. Novartis International AG Sanofi SA GlaxoSmithKline plc Eli Lilly and Company Amgen Inc. Asahi Kasei Corporation Teva Pharmaceutical Industries Ltd. Astellas Pharma Inc. Daiichi Sankyo Company, Limited Mylan N.V. Sandoz International GmbH Daiichi Sankyo Company Limited Aurobindo Pharma Limited Cipla Limited Dr. Reddy's Laboratories Ltd. Hikma Pharmaceuticals PLC Celltrion Inc. Amneal Pharmaceuticals Inc Cadila Healthcare Limited Lupin Limited Biocon Limited Torrent Pharmaceuticals Ltd. Jubilant Life Sciences Limited Ajanta Pharma Limited For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Denosumab Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
29-05-2025
- Business
- Yahoo
Denosumab Market Report 2025-2029 & 2034: Strategic Collaborations and Digital Health Pave the Way for Innovations, First-Line Treatment Boyoubei Gains Traction
Explore the booming denosumab market, projected to reach $5.59 billion by 2029 with a CAGR of 10.9%. Key growth drivers include osteoporosis prevalence, innovative treatments, and strategic partnerships. Major players like Amgen and Boan Biotech are at the forefront, with North America leading and Asia-Pacific emerging rapidly. Denosumab Market Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Denosumab Market Report 2025" has been added to offering. The denosumab market has experienced robust growth, increasing from $3.27 billion in 2024 to an expected $3.7 billion in 2025, registering a CAGR of 13.1%. This growth has been supported by clinical trials, research advancements, FDA approvals, an increased focus on bone health, and strategic partnerships. As the demand continues, projections indicate the market will reach $5.59 billion by 2029, with a CAGR of 10.9% for the forecast period. This anticipated growth is linked to a rising incidence of bone metastases and advancements in both cancer therapies and osteoporosis awareness. Recent studies, including one from the National Center for Biotechnology Information, highlight the prevalence of osteoporosis, with figures such as a 12.7% prevalence in women diagnosed by physicians in Canada. These statistics underscore the expanding need for effective treatments like denosumab, which targets bone resorption, thereby aiding in reducing fracture risks. Key market players are enhancing their offerings, as seen with Boan Biotech's November 2022 introduction of Boyoubei, a denosumab biosimilar. Securing approval from China's National Medical Products Administration, this biosimilar stands unique as the first to receive global marketing approval. Strategies include penetration into the U.S. and European markets with hopes to impact osteoporosis treatment guidelines. Strategic collaborations are shaping the market. For instance, in June 2022, Organon entered into a partnership with Henlius to commercialize biosimilar candidates referencing Prolia and Xgeva (Denosumab). This alliance emphasizes Organon's commitment to affordable healthcare, particularly focusing on women's health. Major companies in this market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, and Amgen Inc., among others. With North America leading the market in 2024, Asia-Pacific is expected to be the fastest-growing region due to rising healthcare advancements and awareness. The denosumab market includes sales of calcium and vitamin D supplements, with values representing factory-gate sales, encompassing the goods sold by manufacturers to various entities. The market also covers comprehensive reports addressing market size, regional shares, and detailed segments, providing a holistic perspective of industry trends. This market, valued in USD unless specified, includes revenues from direct sales, highlighting its importance across multiple geographies, including Asia-Pacific, Western and Eastern Europe, North America, and beyond. Denosumab, as a monoclonal antibody, plays a critical role in treating bone-related conditions, specifically osteoporosis and bone metastases, revealing its ongoing importance in the healthcare landscape. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $3.7 Billion Forecasted Market Value (USD) by 2029 $5.59 Billion Compound Annual Growth Rate 10.9% Regions Covered Global Scope: Markets Covered: By Drug Classification:Prolia, Xgeva, Others By Type:60 mg, 120 mg By End-Users:Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers Companies Featured Johnson & Johnson F. Hoffmann-La Roche Ltd. Novartis International AG Sanofi SA GlaxoSmithKline plc Eli Lilly and Company Amgen Inc. Asahi Kasei Corporation Teva Pharmaceutical Industries Ltd. Astellas Pharma Inc. Daiichi Sankyo Company, Limited Mylan N.V. Sandoz International GmbH Daiichi Sankyo Company Limited Aurobindo Pharma Limited Cipla Limited Dr. Reddy's Laboratories Ltd. Hikma Pharmaceuticals PLC Celltrion Inc. Amneal Pharmaceuticals Inc Cadila Healthcare Limited Lupin Limited Biocon Limited Torrent Pharmaceuticals Ltd. Jubilant Life Sciences Limited Ajanta Pharma Limited For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Denosumab Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Better Weight Loss Stock: Amgen or Viking Therapeutics?
Amgen's weight loss candidate reported mixed phase 2 data, but the company has other weapons. Viking Therapeutics' leading anti-obesity program aced mid-stage studies, and it's not its only promising candidate. Deciding between these two stocks might come down to each investor's style, priorities, and risk tolerance. 10 stocks we like better than Amgen › Investors looking to cash in on the fast-growing market for weight management medicines will naturally turn to the two leaders in this area, Eli Lilly and Novo Nordisk. However, several other companies seem to have somewhat promising prospects in this field. This group includes Amgen (NASDAQ: AMGN) and Viking Therapeutics (NASDAQ: VKTX), two drugmakers that have produced phase 2 clinical trial data for their leading weight management candidates. Despite these positive clinical developments, Amgen and Viking Therapeutics have performed poorly on the stock market in the past 12 months, though progress in this area might eventually help them bounce back. But which of these two biotechs should investors trying to profit from the rapid spending on anti-obesity medicines put their money in? Amgen's leading weight loss candidate is called MariTide. In November, the biotech reported that in a phase 2 study, the medicine led to an average weight loss of about 20% in overweight or obese patients after 52 weeks, with no weight loss plateau observed. Importantly, MariTide is administered subcutaneously once a month -- the current weight management leaders are taken once weekly. A less frequent dosing could appeal to many patients. The market expected greater weight loss in this study. That's why Amgen's shares fell after it released its phase 2 results. However, the company's data still makes it somewhat likely that it will go on to carve out a solid niche in the rapidly growing weight loss area, although it won't dethrone the leaders. Further, Amgen's prospects go well beyond its work in the anti-obesity market. The company's deep lineup allows it to generate consistent revenue and profits. In the first quarter, Amgen's sales increased by 9% year over year to $8.1 billion, while its adjusted earnings per share came in at $4.90, 24% higher than the year-ago period. Amgen has several growth drivers. Tezspire, an asthma medicine, is performing well, as is Prolia, a treatment for osteoporosis (a bone disease) in postmenopausal women. Amgen also has a deep pipeline of investigational products besides MariTide that will eventually lead to brand-new medicines. Lastly, it is an excellent dividend stock. It offers a forward yield of 3.5% -- compared to the S&P 500 index's average of 1.3% -- and has increased its payouts by 201.3% in the past 10 years. Amgen could generate strong returns over the long run even if MariTide doesn't pan out. Viking Therapeutics is a clinical-stage biotech. The company's VK2735, its weight management candidate, looks promising. Last year, it reported that at the highest dose, the drug led to a placebo-adjusted mean weight loss of 13.1% (or 14.7% from baseline) after a mere 13 weeks. VK2735 is in the same class of drugs as Eli Lilly's Zepbound. It mimics the action of two gut hormones: GLP-1 and GIP. That doesn't guarantee that it will achieve the same kind of success, but so far, the data looks highly encouraging. Viking Therapeutics has other candidates. The company's VK2809 targets metabolic dysfunction-associated steatohepatitis. It delivered solid phase 2 results last year. Viking Therapeutics is also developing an oral formulation of VK2735 that is currently in mid-stage studies, while VK0214 is an investigational treatment for a rare, nervous system disorder called X-linked adrenoleukodystrophy. There is no approved treatment for the disease yet. Viking Therapeutics carries above-average risk, as do all biotech companies without a single product on the market. But if VK2735 aces phase 3 results and earns approval -- and Viking's other candidates pan out as well -- the stock could deliver substantial returns. Amgen is a well-established company that generates consistent financial results. It also pays a dividend. It is a far better option for low-risk, income-seeking investors. There is no contest there. However, Viking Therapeutics has far more upside potential. If the smaller biotech can deliver solid pipeline and regulatory progress in the next few years, its shares will likely skyrocket. Note that the company also has significant potential drawbacks. It could be more appealing for investors with a higher tolerance for volatility. Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $644,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $807,814!* Now, it's worth noting Stock Advisor's total average return is 962% — a market-crushing outperformance compared to 169% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool has positions in and recommends Amgen. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Better Weight Loss Stock: Amgen or Viking Therapeutics? was originally published by The Motley Fool
Yahoo
20-05-2025
- Business
- Yahoo
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
Amgen AMGN and Bristol Myers Squibb BMY are among the largest global biotechnology companies with broad and diverse portfolios. Amgen boasts one of the largest portfolios in the biotech industry with a strong presence in the oncology, cardiovascular disease, inflammation, bone health and rare disease markets. Bristol Myers is focused on discovering, developing and delivering transformational drugs for oncology, hematology, immunology, cardiovascular, neuroscience and other diseases. Both of these biotech giants have established strong footholds in their respective target markets, delivering consistent returns to shareholders. In such a scenario, choosing one stock over another can be challenging. Let us delve into their fundamentals, potential growth prospects, challenges and valuation levels to make a prudent choice. With a vast global footprint, Amgen's diverse portfolio has positioned it well in the evolving biotech industry. Growth products like Prolia, Xgeva, Evenity, Vectibix, Nplate and Kyprolis and Blincyto have performed well on consistent label expansions. Robust growth from these products has stabilized the company's revenue base in the face of declining sales from legacy drugs. However, increased pricing headwinds and competitive pressure are negatively impacting the sales of many products. Sales of best-selling drugs, Prolia and Xgeva, are expected to decline in 2025, mainly from the second half, due to biosimilar competition. Nonetheless, Repatha, a key drug in Amgen's arsenal, is driving the growth trajectory. The approval of Tezspire/tezepelumab to treat severe asthma has also strengthened the company's portfolio. Amgen has promising candidates in its pipeline, which represent significant commercial potential. Amgen plans to conduct a broad phase III program on MariTide across obesity, obesity-related conditions and type-II diabetes. Amgen expects data readouts from the ongoing phase II study in type II diabetes and part II of the ongoing phase II study in obesity in the second half of 2025. Amgen also boasts a strong biosimilars portfolio. Approvals of Wezlana and Pavblu have strengthened this portfolio. With a robust cash balance, Amgen is continually seeking strategic deals to expand its business. The acquisition of Horizon Therapeutics has significantly expanded Amgen's rare disease business by adding several rare disease drugs, including Tepezza, Krystexxa and Uplizna, to its portfolio. BMY's Growth Portfolio, comprising drugs like Reblozyl, Breyanzi, Camzyos and Opdualag, has stabilized its revenue base amid generic competition for its legacy drugs. Thalassemia drug Reblozyl has put up a stellar performance since its approval, with strong growth in the United States and international markets. The drug is expected to contribute significantly in the coming decade. Sales of its oncology drug, Opdualag, have also been robust, fueling the top line. Strong growth in the U.S. market and encouraging uptake in newly launched markets have boosted sales. Strong momentum in Camzyos should further drive growth. Opdivo continues to maintain momentum on consistent label expansions. The FDA approval of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use should help extend the impact of its immuno-oncology franchise to patients into the next decade. Other drugs like Zeposia and Krazati should also contribute to top-line growth. The company has made strategic acquisitions to broaden its portfolio and drive top-line growth. The recent FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia in adults, was approved under the brand name Cobenfy. The approval of Cobenfy for schizophrenia broadens BMY's portfolio and validates the acquisition of Karuna Therapeutics. While the newer drugs boost sales, generic competition for legacy drugs, which account for the majority of total revenues, is a significant headwind and will affect top-line growth in the near term. Legacy Portfolio revenues declined 20% in the first quarter due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the U.S. Medicare Part D redesign effect. Nonetheless, BMY is looking to boost its bottom line through cost-cutting initiatives. While BMY's strategy of acquiring companies with promising drugs and candidates is encouraging, this has resulted in substantial debt to finance these acquisitions. As of March 31, 2025, the company had cash and equivalents of $12.1 billion and a long-term debt of $46.1 billion. The Zacks Consensus Estimate for AMGN's 2025 sales implies a year-over-year increase of 5.31%, and that for earnings per share (EPS) suggests a year-over-year improvement of 4.79%. EPS estimates for 2025 have moved north in the past 60 days. However, the metric for 2026 has moved south during the same time frame. Image Source: Zacks Investment Research The Zacks Consensus Estimate for BMY's 2025 sales implies a year-over-year decrease of 4.10% while that for EPS suggests a year-over-year increase of 499.13%. EPS estimates for 2025 have moved north in the past 60 days, but the same for 2026 has remained unchanged during the said timeframe. Image Source: Zacks Investment Research From a price-performance perspective, AMGN has fetched better returns than BMY so far this year. Shares of AMGN have gained 6.2%, while those of BMY have lost 15.5%. The industry has declined 6.2% in the said period. Image Source: Zacks Investment Research From a valuation standpoint, as the biotech industry has very few players with approved drugs, we use the P/E ratio of the large-cap pharma industry to compare these companies. Going by the same, AMGN is more expensive than BMY. AMGN's shares currently trade at 13X forward earnings, higher than 7.10 for Source: Zacks Investment Research AMGN and BMY's attractive dividend yield is a strong positive for investors. However, BMY's dividend yield of 5.30% is higher than AMGN's 3.49%. Large biotech companies are generally considered safe havens for investors interested in this sector. However, with both AMGN and BMY currently carrying a Zacks Rank #3 (Hold), choosing one stock over the other is a complex task. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. AMGN's strong and diverse portfolio should enable it to maintain growth. Key drugs like Evenity and Repatha, as well as newer drugs like Tavneos and Tezspire, continue to drive growth and offset the revenue decline from oncology biosimilars and legacy drugs like Enbrel. BMY's efforts to revive the top line in the face of generic challenges for key drugs are commendable. However, we believe there is still time before the efforts reap a harvest for the company. The outlook for 2025 indicates challenges as of now. Hence, AMGN is a better pick at present (despite its pricey valuation) as we believe there is room for growth buoyed by solid fundamentals and recent positive estimate revisions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
FDA biosimilar approvals set for record-breaking year amid US pricing reforms
2024 saw the highest number of biosimilars approved by the US Food and Drug Administration (FDA) in a calendar year, with this year set to break this record again, analysis suggests. The FDA approved 19 biosimilars last year, a sharp jump from the five greenlit by the agency in 2023. GlobalData's Bio/Pharmaceutical Outsourcing Report notes that momentum for biosimilars is set to accelerate. A total of 18 biologics will lose patent protection in 2025, up from 14 in 2024. This includes blockbuster products such as Amgen's Prolia (denosumab) and Roche's Perjeta (pertuzumab). GlobalData, the parent company of Pharmaceutical Technology, states that projections indicate that 2025 could surpass 2024's milestone trend. Debutants in 2024 included Amgen's Wezlana (ustekinumab-auub), the first of six biosimilars to Johnson & Johnson's (J&J's) blockbuster autoimmune drug Stelara (ustekinumab). Stelara generated $10.9bn in 2023, making it one of the top-selling drugs to gain biosimilar competition last year. There were also five new drugs referencing the ophthalmology drug Eylea (aflibercept) that gained FDA approval in 2024. Regeneron's Eylea saw sales of $5.89bn in sales in 2023 before rivals entered the market. It was also a strong 2024 for drugmakers in the space. Sandoz reported that biosimilar sales grew 30%, contributing to the company's $10.4bn net sales. Samsung Bioepis, another biosimilar specialist, posted a record-breaking financial year in 2024, with sales and operating profit up by 51% and 112%, respectively. The spike in approvals is set against a backdrop of governmental pushes to increase reference drug use. US President Donald Trump signed an executive order (EO) earlier this week that overhauled pharmaceutical pricing in the country. According to a Reuters article, pharma companies launched new US drugs at prices 35% higher in 2023, compared to those launched in 2022. Biosimilars and generics can be as much as 80% cheaper than branded alternatives. Kathryn Kinch, senior pharma product manager at GlobalData, said: 'Increased approvals of biosimilars are likely to lower biologic prices, enhancing consumer demand and competition among drug companies, which will benefit contract manufacturing organisations through higher biosimilar volumes.' As per a White House fact sheet, the EO 'increases the availability of generics and biosimilars'. Trump already pushed the FDA to expedite the development of lower-cost generic medicines and biosimilars in his first term as president. Juliana Reed, executive director of the Biosimilars Forum, said: '[We are] pleased to see the Trump Administration announce meaningful action on several fronts, including reforms to make biosimilars available quickly and efficiently to all Americans who need them. The EO also accelerates approval of biosimilars through the FDA and requires transparency and fairness from middlemen who prioritise profits over patients. 'Safe, effective, and lower-cost biosimilars are the clear answer to America's skyrocketing prescription drug costs.' "FDA biosimilar approvals set for record-breaking year amid US pricing reforms" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
